📰 Trvn News
Trvn News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Trvn. Real-time updates on events, politics, business and more.
May 4, 2024
StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of Trevena in a report on Tuesday, April 2nd. Get Our Latest […]
May 2, 2024
StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Trevena in a research report […]
April 24, 2024
Research analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Trevena in a report on Tuesday, […]
April 8, 2024
Research analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Trevena in […]
April 2, 2024
Trevena (NASDAQ:TRVN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on Trevena in a research report on Friday. They set a “sell” rating […]
January 29, 2024
StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Trevena Stock Performance NASDAQ:TRVN opened at $0.64 on Thursday. Trevena has a 1-year low of $0.51 and a 1-year high of $3.28. The company has a debt-to-equity […]
January 17, 2024
Equities researchers at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Trevena Price Performance TRVN stock opened at $0.69 on Wednesday. Trevena has a 1 year low of $0.51 and a 1 […]
January 5, 2024
StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Trevena Price Performance TRVN opened at $0.73 on Monday. Trevena has a 1-year low of $0.51 and a 1-year high of $3.28. The company has a current […]
January 4, 2024
StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report sent to investors on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Trevena Stock Performance NASDAQ:TRVN opened at $0.72 on Monday. The company has a debt-to-equity ratio of 8.35, a quick ratio of 6.27 and […]
December 31, 2023
Trevena, Inc. (NASDAQ:TRVN – Get Free Report) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 286,800 shares, a decrease of 41.8% from the November 30th total of 493,000 shares. Based on an average daily volume of 334,300 shares, the short-interest ratio is currently 0.9 days. […]